Tempest Therapeutics Inc (TPST)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen R. Brady
Employees:
20
7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO, CA, 94080
415-798-8589

Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.

Data derived from most recent annual or quarterly report
Market Cap 19.539 Million Shares Outstanding10.562 Million Avg 30-day Volume 123.611 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.46
Price to Revenue0.0 Debt to Equity1.8544 EBITDA-32.57 Million
Price to Book Value2.912 Operating Margin0.0 Enterprise Value29.34 Million
Current Ratio3.285 EPS Growth-2.295 Quick Ratio3.052
1 Yr BETA 1.2459 52-week High/Low 4.21 / 1.06 Profit Margin0.0
Operating Cash Flow Growth-20.61 Altman Z-Score-7.0372 Free Cash Flow to Firm -48.49 Million
View SEC Filings from TPST instead.

View recent insider trading info

Tempest Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TPST (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TPST

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-05 by TROJANOWSKI JUSTIN
  • 4: filed on 2022-10-04 by TROJANOWSKI JUSTIN
  • 3: filed on 2022-10-04 by TROJANOWSKI JUSTIN
  • 4: filed on 2022-06-22 by LORENZO PIERRE
  • 4: filed on 2022-06-22 by MAESTAS NICHOLAS
  • 4: filed on 2022-06-22 by WHITING SAMUEL
  • 4: filed on 2022-06-22 by DUBENSKY THOMAS W.
  • 4: filed on 2022-06-22 by BRADY STEPHEN R
  • 4: filed on 2022-06-22 by PELLIZZARI CHRISTINE A
  • 4: filed on 2022-06-22 by NICHOL GEOFFREY

    • Events (8k)

  • 8-K: filed on 2023-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-31:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-22:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-29:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BRADY STEPHEN R CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 177,300 2023-01-03 2

    DUBENSKY THOMAS W. PRESIDENT

    • Officer
    • Director
    		 102,700 2023-01-03 2

    WHITING SAMUEL CHIEF MEDICAL OFFICER

    • Officer
    		 69,700 2023-01-03 2

    MAESTAS NICHOLAS VP OF STRATEGY AND FINANCE

    • Officer
    		 38,425 2023-01-03 2

    TROJANOWSKI JUSTIN CORPORATE CONTROLLER

    • Officer
    		 20,300 2023-01-03 3

    LORENZO PIERRE CORPORATE CONTROLLER

    • Officer
    		 8,477 2022-06-21 1

    PELLIZZARI CHRISTINE A

    • Director
    		 3,500 2022-06-17 1

    NICHOL GEOFFREY

    • Director
    		 3,500 2022-06-17 1

    RAAB MICHAEL

    • Director
    		 3,500 2022-06-17 1

    WOIWODE THOMAS

    • Director
    		 3,500 2022-06-17 1

    SIMANTOV RONIT

    • Director
    		 3,500 2022-06-17 1

    VERSANT VENTURE CAPITAL VI, L.P.

    VERSANT VENTURES VI GP, L.P.

    VERSANT VENTURES VI GP-GP, LLC

    VERSANT VANTAGE II, L.P.

    VERSANT VANTAGE II GP, L.P.

    VERSANT VANTAGE II GP-GP, LLC

    VERSANT VENTURES IV, LLC

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT SIDE FUND IV, L.P.

    • 10% Owner
    		 4,295,055 2022-04-29 0

    VERSANT VANTAGE II, L.P.

    VERSANT VANTAGE II GP, L.P.

    VERSANT VANTAGE II GP-GP, LLC

    • 10% Owner
    		 2,118,644 2022-04-29 0

    ROCK SPRINGS CAPITAL MANAGEMENT LP

    ROCK SPRINGS CAPITAL LLC

    ROCK SPRINGS CAPITAL MASTER FUND LP

    • 10% Owner
    		 823,654 2021-12-30 0

    XU STELLA

    • Director
    		 6,635 2021-07-01 0

    VERSANT VENTURE CAPITAL VI, L.P.

    VERSANT VENTURES VI GP, L.P.

    VERSANT VENTURES VI GP-GP, LLC

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT VENTURES IV, LLC

    VERSANT SIDE FUND IV, L.P.

    • 10% Owner
    		 2,176,411 2021-06-25 0

    OWENS JULIA C. EXECUTIVE CHAIR

    • Officer
    • Director
    		 24,000 2021-03-17 0

    ARCUDI III LOUIS J PRESIDENT AND CEO

    • Officer
    • Director
    		 400,000 2021-02-26 0

    MINAI-AZARY JENNIFER LYNN CHIEF FINANCIAL OFFICER

    • Officer
    		 110,000 2021-02-26 0

    HOWE JOHN P MD

    • Director
    		 0 2020-06-22 0

    GALLAGHER CAROL GILTNER

    • Director
    		 0 2020-06-22 0

    HEDLEY MARY LYNNE

    • Director
    		 0 2020-06-22 0

    HINDMAN JAMES M.

    • Director
    		 0 2020-06-22 0

    NUECHTERLEIN CAROLE

    • Director
    		 0 2020-06-22 0

    DABLE HABIB J

    • Director
    		 0 2020-06-22 0

    JOSEPH TAMARA L GENERAL COUNSEL AND SECRETARY

    • Officer
    		 0 2020-05-25 0

    ZEIDAN RYAN CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2020-05-25 0

    ARBET-ENGELS CHRISTOPHE CHIEF MEDICAL OFFICER

    • Officer
    		 0 2020-05-25 0

    WHITCOMB RANDALL W

    • Director
    		 0 2019-06-20 0

    BRINZA JEFFERY M. SEC., CAO AND GENERAL COUNSEL

    • Officer
    		 0 2019-01-15 0

    MOHIDEEN PHARIS CHIEF MEDICAL OFFICER

    • Officer
    		 0 2019-01-15 0

    BARRIS PETER J

    • 10% Owner
    		 1,766,407 2018-12-07 0

    ALDRICH RICHARD

    • Director
    		 No longer subject to file 2018-12-07 0

    MOTT DAVID M

    • 10% Owner
    		 1,766,407 2018-12-07 0

    MAKOWER JOSHUA

    • 10% Owner
    		 1,766,407 2018-12-07 0

    SANDELL SCOTT D

    • 10% Owner
    		 1,766,407 2018-12-07 0

    KOZIN MARC D

    • Director
    		 No longer subject to file 2018-12-07 0

    FISHER MARY

    • Director
    		 No longer subject to file 2018-12-07 0

    BASKETT FOREST

    • 10% Owner
    		 1,766,407 2018-12-07 0

    FHM VI, L.L.C.

    FHM VI, L.P.

    FRAZIER HEALTHCARE VI, L.P.

    • 10% Owner
    		 1,396,615 2018-12-07 0

    SONSINI PETER W.

    • 10% Owner
    		 1,766,407 2018-12-07 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    		 1,766,407 2018-12-07 0

    NEW ENTERPRISE ASSOCIATES 15, L.P.

    NEA PARTNERS 15, L.P.

    NEA 15 GP, LLC

    • 10% Owner
    		 1,766,407 2018-12-07 0

    MAKHZOUMI MOHAMAD

    • 10% Owner
    		 1,766,407 2018-12-07 0

    KROEGER CHRISTOPHER A. CHIEF EXECUTIVE OFFICER

    • Officer
    		 No longer subject to file 2018-12-07 0

    GILLIS JONATHAN SENIOR VICE PRESIDENT, FINANCE

    • Officer
    		 No longer subject to file 2018-12-07 0

    LILLIE JAMES WOODRUFF CHIEF SCIENTIFIC OFFICER

    • Officer
    		 No longer subject to file 2018-12-07 0

    CAPELLO JEFFREY D

    • Director
    		 0 2018-07-04 0

    SEXTON JOHN

    • Director
    		 0 2018-07-04 0

    DIPP MICHELLE EXECUTIVE CHAIR

    • Officer
    • Director
    		 0 2017-06-21 0

    MALLEY THOMAS

    • Director
    		 204,981 2017-06-13 0

    COUTURIER CHRISTOPHE CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2017-03-02 0

    CHAPMAN PAUL W.D. CHIEF OPERATING OFFICER

    • Officer
    		 3,100 2016-05-10 0

    STOCK HARALD F.

    • Director
    		 266,422 2016-01-05 0

    YOUNG JEFFREY E CHIEF FINANCIAL OFFICER

    • Officer
    		 53,750 2015-12-03 0

    TZIANABOS ARTHUR PRESIDENT AND CSO

    • Officer
    		 26,400 2015-12-03 0

    MCNEELY THERESA EVP, CHIEF COMM. OFFICER

    • Officer
    		 400 2015-04-08 0

    LONGWOOD FUND, L.P.

    • 10% Owner
    		 No longer subject to file 2015-01-14 0

    HARDING DAVID CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2014-12-09 0

    LAWTON ALISON FRANCIS CHIEF OPERATING OFFICER

    • Officer
    		 0 2013-03-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 22:15:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 21:45:05 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 21:15:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 20:45:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 20:15:05 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 19:45:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 19:15:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 18:45:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 18:15:03 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 17:45:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 17:15:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 16:45:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 16:15:03 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 15:45:03 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 15:15:03 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 14:45:05 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 14:15:04 UTC -88.2251 93.2951 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 13:45:05 UTC -105.2425 110.3125 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 13:15:03 UTC -105.2425 110.3125 250000
    TEMPEST THERAPEUTICS INC TPST 2023-05-29 12:45:03 UTC -105.2425 110.3125 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund TPST -400.0 shares, $-928.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments